<DOC>
	<DOC>NCT01943721</DOC>
	<brief_summary>The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.</brief_summary>
	<brief_title>A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Written informed consent Primary openangle glaucoma or ocular hypertension in both eyes Bestcorrected distance vision of 20/100 or better Stable visual field Cuptodisc ratio greater than 0.8 Laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12 months Corneal refractive surgery within prior 6 months Past history of any incisional surgery for glaucoma at any time Corneal abnormalities that would interfere with tonometry readings Current participation in an investigational drug or device study or participation in such a study within 30 days of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>